Mural Oncology PLC

Mural Oncology PLC(MURA)股票分析

$2.040

0.000 (0.00%)收盤時

Loading chart…
High
2.040
Open
2.030
VWAP
2.04
Vol
127.78K
Mkt Cap
Low
2.030
Amount
260.24K
EV/EBITDA, TTM
0.55

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

估值指標

The current forward P/E ratio for Mural Oncology PLC (MURA) is -0.78, compared to its 5-year average forward P/E of -0.64.

Forward P/E

Fair
5Y Average P/E
-0.64
Current P/E
-0.78
高估
-0.33
低估
-0.94

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.82
Current EV/EBITDA
0.55
高估
1.48
低估
0.15

Forward P/S

Fair
5Y Average P/S
0.08
Current P/S
0.00
高估
0.64
低估
-0.47

Alphio AI Price Scenarios for MURA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MURA

$2.80

情境價格

B

Base

Base · 50%MURA

$2.62

情境價格

B

Bear

Bear · 25%MURA

$2.13

情境價格

事件時間軸

2025-12-05 (ET)

09:10:00

XOMA Completes Acquisition of Entire Share Capital of Mural Oncology

07:50:00

Mural Oncology Announces Scheme of Arrangement Effective

2025-11-26 (ET)

09:04:43

Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion

2025-10-24 (ET)

16:29:41

Mural Oncology Shareholders Give Green Light to XRA 5 Corp. Acquisition

2025-08-20 (ET)

08:35:20

XRA 5 Corp. to Purchase Mural Oncology for $2.035-$2.24 per Share in Cash

資訊

MURA FAQ — answered by Alphio AI

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始